Platelet Reactivity Clinical Trial
Official title:
Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
Clopidogrel administration is commonly prescribed in patients undergoing percutaneous coronary intervention, in patients with previous stroke and in patients under chronic hemodialysis via fistulae. Patients with chronic renal failure present lower clopidogrel response compared to those with normal renal function. Ticagrelor is a new oral direct-acting antagonist, which provides greater platelet inhibition in both clopidogrel responders and non-responders. It has also been shown that in patients with chronic kidney disease (creatinine clearance <60 mL/min)ticagrelor achieved an absolute risk reduction of cardiovascular death, myocardial infarction, and stroke greater than that of patients with normal renal function. Clopidogrel resistant patients as assessed by VerifyNow P2Y12(Accumetrics)will be administered after informed consent ticagrelor 90 mg twice daily for 15 days. Platelet reactivity will be determined at the end of the treatment period. Bleeding events, major adverse cardiac events and any side effects until Day 15 will be reported in a descriptive manner.
n/a
Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02808039 -
Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial
|
N/A | |
| Completed |
NCT01961856 -
Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.
|
Phase 3 | |
| Recruiting |
NCT03525145 -
Platelet Reactivity And Clinical ThrombotIC Events Study
|
||
| Completed |
NCT01463150 -
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
|
Phase 4 | |
| Completed |
NCT01463163 -
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
|
Phase 4 | |
| Recruiting |
NCT03614832 -
Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD
|
Phase 4 | |
| Completed |
NCT01835353 -
High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
|
Phase 3 | |
| Completed |
NCT04001894 -
Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease
|
Phase 4 | |
| Recruiting |
NCT05773989 -
Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy
|
Phase 4 | |
| Completed |
NCT00827346 -
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty
|
Phase 2/Phase 3 | |
| Completed |
NCT00976196 -
Platelet Hyperreactivity Project
|
N/A | |
| Recruiting |
NCT05367336 -
Platelet Reactivity With Fentanyl, Morphine, or no Narcotic
|
Early Phase 1 | |
| Completed |
NCT03679091 -
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
|
Phase 4 | |
| Recruiting |
NCT05657041 -
Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease
|
Phase 2/Phase 3 |